Across treatments, rozanolixizumab and batoclimab were most effective, though rozanolixizumab carried increased risk of adverse events (AEs) and serious AEs. Data from a new analysis of a range of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results